Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Jacob Wagner, M.D.

Concepts (167)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hemangiosarcoma620242133.620 Why?
Sarcoma12202417991.940 Why?
Chondrosarcoma420223011.780 Why?
Sarcoma, Synovial320241571.030 Why?
Bone Neoplasms6202225590.980 Why?
Osteosarcoma420229080.950 Why?
Soft Tissue Neoplasms6202311630.910 Why?
Hemangioendothelioma120231120.810 Why?
Hemangioendothelioma, Epithelioid12023520.810 Why?
Anthracyclines220212850.770 Why?
Gastrointestinal Stromal Tumors320246160.770 Why?
Ifosfamide320242330.770 Why?
Liposarcoma220222880.690 Why?
Neoplasms, Connective and Soft Tissue12020340.690 Why?
Antineoplastic Combined Chemotherapy Protocols82024118580.680 Why?
Doxorubicin5202322260.630 Why?
Phosphatidylcholines220174030.610 Why?
Vascular Endothelial Growth Factor Receptor-2120215480.600 Why?
Leiomyosarcoma120224250.590 Why?
Receptor, EphA212017410.550 Why?
Antigens, Neoplasm2202119950.530 Why?
Neoplasms, Second Primary1202410560.520 Why?
Rare Diseases120216290.510 Why?
Vincristine1201710370.470 Why?
Protein-Tyrosine Kinases1202424230.470 Why?
MAP Kinase Signaling System1202114890.450 Why?
Liposomes120177860.420 Why?
Liposarcoma, Myxoid22024600.400 Why?
Up-Regulation1202141300.390 Why?
RNA Interference1201728290.300 Why?
Gene Expression Regulation, Neoplastic2202186030.300 Why?
RNA, Small Interfering1201734190.290 Why?
Breast Neoplasms22024210690.260 Why?
SEER Program2202214430.260 Why?
Nanoparticles1201719660.240 Why?
Phenylurea Compounds220175360.220 Why?
Retrospective Studies112024815370.210 Why?
Antineoplastic Agents52017136310.190 Why?
Sarcoma, Kaposi120243760.190 Why?
Vesicular Transport Proteins120243760.180 Why?
Humans3720247659260.180 Why?
Young Adult112024598570.180 Why?
Ubiquitin Thiolesterase120244550.180 Why?
Mesna12020620.180 Why?
Interleukin-15120211860.170 Why?
Adult1820242230880.160 Why?
Protective Agents120201510.160 Why?
Aged1520241711630.160 Why?
Adjuvants, Immunologic120249930.150 Why?
Pyrimidinones120213840.150 Why?
Antineoplastic Agents, Alkylating120226140.150 Why?
Mastectomy, Segmental120239640.150 Why?
High-Throughput Nucleotide Sequencing2202436610.150 Why?
Neoplasm Recurrence, Local2202093730.150 Why?
In Situ Hybridization, Fluorescence1202425100.150 Why?
Cell Proliferation42021104260.150 Why?
Middle Aged1520242230160.140 Why?
Ribosomal Protein S6 Kinases, 70-kDa120171010.140 Why?
Xenograft Model Antitumor Assays3202136040.140 Why?
Mice, Nude2202136080.140 Why?
Molecular Targeted Therapy3202028230.140 Why?
Male1820243638150.140 Why?
Genetic Heterogeneity120207350.130 Why?
Solitary Fibrous Tumors12017700.130 Why?
Female1820243961410.130 Why?
Thrombocytopenia1202411720.130 Why?
Kaplan-Meier Estimate3202265030.130 Why?
Receptors, Antigen, T-Cell2202325700.130 Why?
Pyridones120218160.130 Why?
Leukocytes, Mononuclear1202218520.120 Why?
Incidence22024215130.120 Why?
Retinal Vein Occlusion120161470.120 Why?
Pyridines2201728850.120 Why?
Quinazolines1202113660.120 Why?
Anemia1202415140.110 Why?
Membrane Proteins2202178470.110 Why?
Treatment Outcome92021651940.110 Why?
Cancer Vaccines1202110420.110 Why?
Tumor Cells, Cultured1202161010.110 Why?
Aged, 80 and over72024594960.100 Why?
Neoplasm Metastasis2202148820.100 Why?
Survival Analysis32021100860.100 Why?
Tissue Distribution1201722700.100 Why?
Prognosis32022298900.100 Why?
Adolescent72024888110.100 Why?
Child52024805680.100 Why?
Drug Evaluation, Preclinical1201713310.100 Why?
Proto-Oncogene Proteins1202445200.090 Why?
Developing Countries1202429130.090 Why?
Immunotherapy, Adoptive1202115040.090 Why?
Macaca mulatta1201723410.090 Why?
Lymphocyte Activation1202155000.090 Why?
Ovarian Neoplasms2201749040.080 Why?
Angiogenesis Inhibitors2201720460.080 Why?
Apoptosis3202195050.080 Why?
Neoplasm Invasiveness1201735990.080 Why?
Neoplasm Proteins1202135920.080 Why?
CD4-Positive T-Lymphocytes1202144050.080 Why?
Gastrointestinal Neoplasms120169580.080 Why?
Proto-Oncogene Proteins c-akt1201724550.080 Why?
Uterine Neoplasms1201714250.080 Why?
Phosphoproteins1201724440.080 Why?
Chemotherapy, Adjuvant1201635420.070 Why?
T-Lymphocytes22023102560.070 Why?
Disease-Free Survival1201768380.070 Why?
Adaptor Proteins, Signal Transducing1201728970.070 Why?
Macrophages1202157720.070 Why?
Neovascularization, Pathologic1201626270.060 Why?
Aspirin1201631350.060 Why?
Databases, Factual1202080600.060 Why?
HLA-A Antigens120242230.050 Why?
Mice32021817820.050 Why?
Antibodies, Monoclonal1202092390.050 Why?
Cross-Sectional Studies12024262820.050 Why?
Cohort Studies12024416800.050 Why?
Survival Rate12015128220.040 Why?
Myeloablative Agonists120212150.040 Why?
Prospective Studies22023548070.040 Why?
Toll-Like Receptor 4120235870.040 Why?
Animals420211687350.040 Why?
Gene Expression Profiling1201595250.040 Why?
CD4 Lymphocyte Count1202425860.040 Why?
Tumor Microenvironment2202239400.040 Why?
HIV Infections12024175310.040 Why?
Cell Line, Tumor32021170600.040 Why?
Cytotoxicity, Immunologic1202113460.040 Why?
Coculture Techniques1202113360.030 Why?
Thromboxanes12016450.030 Why?
Inhibitory Concentration 50120174610.030 Why?
Antibiotics, Antineoplastic120206780.030 Why?
Risk Factors22021748500.030 Why?
Immunity1202210000.030 Why?
Cyclophosphamide1202122320.030 Why?
United States12023729090.030 Why?
Clinical Trials, Phase I as Topic120163290.030 Why?
Retreatment120165980.030 Why?
Immunologic Memory1202113740.030 Why?
Transplantation Conditioning1202116350.030 Why?
Giant Cell Tumor of Bone120151190.030 Why?
Disease Susceptibility1202017870.030 Why?
Antineoplastic Agents, Phytogenic120176150.030 Why?
Necrosis1201716110.030 Why?
Immunoenzyme Techniques1201516950.030 Why?
Proto-Oncogene Proteins c-kit120167230.030 Why?
Fatal Outcome1201618350.020 Why?
Tumor Burden1201718880.020 Why?
Neoadjuvant Therapy1202228950.020 Why?
Protein Kinase Inhibitors2201756910.020 Why?
Paclitaxel1201717260.020 Why?
Combined Modality Therapy1202085220.020 Why?
Pilot Projects1202187240.020 Why?
Infant22021364260.020 Why?
Child, Preschool22021425100.020 Why?
Neoplasm Staging12020111960.020 Why?
Dose-Response Relationship, Drug12016107270.010 Why?
Cell Differentiation12021116390.010 Why?
Proteomics1201539060.010 Why?
Infant, Newborn12021263800.010 Why?
Disease Progression12016136140.010 Why?
Time Factors12021400970.010 Why?
Genetic Predisposition to Disease12020180740.010 Why?
Positron-Emission Tomography1201565420.010 Why?
Transcription Factors12017121290.010 Why?
Disease Models, Animal12016182920.010 Why?
Risk Assessment12017242750.010 Why?
Mutation12020301920.010 Why?
Tomography, X-Ray Computed12015206900.010 Why?
Wagner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (167)
Explore
_
Co-Authors (8)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.